Trial Profile
A Phase 1B Clinical Trial of Dabrafenib, Trametinib Plus Digoxin in Patients With Unresectable or Metastatic BRAF V600 Mutant Melanoma
Status:
Withdrawn prior to enrolment
Phase of Trial:
Phase I
Latest Information Update: 05 Nov 2021
Price :
$35
*
At a glance
- Drugs Dabrafenib (Primary) ; Trametinib (Primary) ; Digoxin
- Indications Malignant melanoma
- Focus Adverse reactions
- 09 May 2018 Status changed from recruiting to withdrawn prior to enrolment as no subjects consented for enrollment on this study.
- 22 Nov 2016 Status changed from not yet recruiting to recruiting.
- 30 Sep 2016 New trial record